Drug Database
FO

formoterol (formoterol, Meda / Formatris Novolizer)

✓ Approved

Meda Co., Ltd. · ADRB2 · 小分子

什么是 formoterol?

formoterol 是一种小分子,由Meda Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

商品名formoterol, Meda, Formatris Novolizer
公司Meda Co., Ltd.
药物类别小分子
分子靶点ADRB2
给药途径Inhaled
状态Approved

作用机制

分子靶点

formoterol 作用于 1 个分子靶点:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

formoterol 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersChronic obstructive pulmonary disease✓ Approved

相关研究文献

PubMedInternational journal of chronic obstructive pulmonary disease2026-11-05

Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study.

Watz Henrik H, Watt Michael M, Morris Tamsin T, Saathoff Matthias M et al.

To evaluate the real-world effectiveness of budesonide/glycopyrronium/formoterol (BGF) fixed-dose combination regarding clinical and patient-reported outcomes (PRO) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) in routine care. This prospective, single-arm observational, multi-center study collected data via electronic forms and PRO questionnaires. The primary outcome evaluated change in COPD assessment test (CAT) scores from baseline to 3 months of therapy. Secondary outcomes included change in the St. George's Respiratory Questionnaire (SGRQ), Treatment Satisfaction Questionnaire for Medication (TSQM-9), and annualized exacerbation rates (AER) over 12 months. The study enrolled 571 patients with COPD from Germany (n=441) and the United Kingdom (UK, n=130) prescribed BGF fixed-dose combination per routine care. Overall, the mean age was 65.5 years (Germany 64.8; UK 68.1), 55.9% were male (Germany 56.5%; UK 53.8%). Baseline CAT was 20.4 (Germany 19.5; UK 23.6), and the SGRQ score was 49.7 (Germany 47.3; UK 58.1). Prior 12-month exacerbations were reported by 35.6% overall (Germany 28.9%; UK 58.6%). Overall, 60.6% had cardiovascular comorbidities, including 46.2% with hypertension; cardiovascular disease rates were similar across countries, but asthma, depression, chronic kidney disease, and osteoarthritis were higher in the UK. At 3 months, CAT improved by -3.28 overall (95% confidence interval [CI] -4.31 to -2.26; Germany -3.49; UK -2.38); minimum clinically important difference was achieved in 58.2% (Germany 58.7%; UK 56.3%); SGRQ improved -7.04 overall (95% CI -9.09 to -5.00; Germany -7.57; UK -4.76); and TSQM-9 Global satisfaction increased 14.7 at 12 months (95% CI 10.61 to 18.85). AER fell from 0.74 to 0.45 (rate ratio 0.60; 95% CI 0.51 to 0.72). BGF fixed-dose combination improved health status, quality of life, and reduced exacerbations in patients in this observational descriptive study. These findings complement evidence from clinical trials and suggest BGF fixed-dose combination has benefits for patients with moderate-to-severe COPD in routine care.

PMID 42985257
阅读全文 →
PubMedThe European respiratory journal2026-11-05

2026 Global Initiative for Asthma (GINA) strategy report: executive summary and key changes.

Reddel Helen K HK, Allan Keith K, Bacharier Leonard B LB, Bonini Matteo M et al.

The Global Initiative for Asthma (GINA) Strategy Report provides a comprehensive, annually updated evidence-based approach to asthma diagnosis, assessment, treatment, and prevention across the lifespan. Its central approach is personalized, iterative care based on the Assess-Adjust-Review cycle for both symptom control and reduction of future risk (including severe exacerbations, persistent airflow limitation, and treatment-related harm).GINA emphasizes objective confirmation of diagnosis wherever possible, and regular assessment of lung function, inhaler technique, adherence, multimorbidity, risk factors (including Type-2 biomarkers), and patient goals and preferences. GINA strongly recommends that all adults, adolescents, children and most preschoolers with asthma should receive inhaled corticosteroid (ICS)-containing treatment. GINA recommends against short-acting beta2-agonist (SABA)-only treatment. For adults/adolescents, GINA Track 1 using low-dose ICS-formoterol, an anti-inflammatory reliever (AIR), either as-needed-only (AIR-only) or as maintenance-and-reliever therapy (MART), is preferred because of its substantial reduction in severe exacerbations compared with SABA-based regimens, and its simplicity. Age-specific treatment pathways in children also emphasize ICS-containing therapy and exacerbation prevention.For difficult-to-treat and severe asthma, GINA provides structured guidance, emphasizing diagnostic verification, optimization of modifiable factors, inflammatory phenotyping, biologic therapy selection, and (as for all patients) systemic corticosteroid stewardship. Acute exacerbation care incorporates long-term preventive treatment, including post-discharge reassessment of management and action plan.Key 2026 updates include expanded AIR options for adults and children, revised guidance on severe asthma and selection of biologic treatment, and substantial updates to acute asthma management.GINA integrates evidence-based management with shared decision-making, self-management education, implementation, and global advocacy to reduce preventable asthma morbidity and mortality.

PMID 42988388
阅读全文 →
PubMedAmerican journal of respiratory and critical care medicine2026-11-03

As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline.

Khurana Sandhya S, Jenkins Alex R AR, Reddel Helen K HK, Akuthota Praveen P et al.

Inhaled corticosteroid (ICS)-containing reliever therapy has demonstrated efficacy in improving asthma outcomes when compared to short-acting beta2-agonists (SABA) alone but remains underutilized. The purpose of this guideline is to provide recommendations surrounding the use of combination ICS-formoterol or ICS+SABA (in combination or separate inhalers) as reliever therapy across the asthma severity spectrum in adolescents and adults. The American Thoracic Society clinical practice guideline panel evaluated six research questions in the PICO format addressing the use of ICS-containing reliever therapy across National Asthma Education and Prevention Program (NAEPP) asthma treatment steps 1-5. The methodology team conducted systematic literature reviews and GRADE assessments, which the panel utilized to inform the recommendations for each specific PICO and overall. In patients at NAEPP steps 1 and 2, the panel made strong recommendations for the use of as-needed-only ICS-SABA or ICS-formoterol over SABA-only therapy, and conditional recommendations over scheduled ICS + as-needed SABA. In patients at NAEPP steps 3-5, the taskforce made a strong recommendation for the use of maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. In patients at NAEPP steps 3-5 who are using scheduled maintenance ICS-LABA, the panel made a conditional recommendation for use of ICS+SABA reliever over SABA reliever. In considering these recommendations, the panel valued the importance of preventing severe exacerbations and considered the risk of SABA-only treatment, as well as ICS and systemic corticosteroid (SCS) exposure. This clinical practice guideline, informed by systematic reviews and GRADE-based appraisals of PICO-framed evidence, makes these evidence-based recommendations for the safe and effective use of ICS-containing reliever therapy in asthma.

PMID 42974958
阅读全文 →
PubMedThe Lancet regional health. Western Pacific2026-10-30

Implementation of the National Asthma Guidelines in New Zealand: a retrospective patient-level study of the change to anti-inflammatory reliever therapy in 324,972 patients.

Cheng Franco Wing Tak FWT, Gong Jiayi J, Tomlin Andrew A, Harrison William W et al.

The updated New Zealand asthma guidelines in 2020, aligning with global asthma guideline recommendations, advocated for a fundamental shift from short-acting β2-agonist (SABA) reliever therapy to anti-inflammatory reliever (AIR) therapy (ICS-formoterol) in adults and adolescents. While aggregate population-level data indicate increased ICS-formoterol dispensings, patient-level changes in medication use remain unclear. We examined medication use patterns to assess early practice changes across the entire asthma population. We conducted a retrospective study using the New Zealand national linked health datasets. Patients aged ≥12 with asthma were identified from hospitalisation and/or dispensing data, and categorised by the complete set of inhaler classes dispensed in the three months preceding their final dispensing date within the baseline (July 2018-June 2020) and post-guideline (June 2020-June 2022) periods. Nine mutually exclusive categories were defined without applying any hierarchy between medications: SABA only; ICS, non-formoterol ICS-LABA, and ICS-formoterol, each with and without a concurrently dispensed SABA; other regimens; and no inhaled medication. Age subgroups (12-44 and ≥ 45 years) were examined. Children aged < 12 years throughout follow-up, who were outside the scope of the recommendation, served as a comparison cohort for difference-in-differences estimation. The cohort included 324,972 patients aged ≥12 years. At baseline, the SABA-only group was the most common (30.5%). Post-guideline, dispensing of the guideline-recommended regimen, ICS-formoterol without SABA, more than doubled from 10.9% to 23.8%, and any ICS-formoterol use rose from 18.9% to 34.5%. The proportion of patients dispensed any SABA fell from 74.1% to 60.8%. Of patients dispensed SABA only pre-guideline, 57.1% were dispensed SABA only again, while 17.6% changed to ICS-formoterol without SABA and 8.1% to ICS-formoterol with SABA. Continuity was high among patients on maintenance therapy (55.9% for ICS, 74.3% for non-formoterol ICS-LABA) and among those already dispensed ICS-formoterol (89.0%). Among post-guideline ICS-formoterol users, 31.1% were also dispensed a SABA, compared with 63.8% of non-formoterol ICS-LABA users and 70.2% of ICS users. Using children aged < 12 years as a comparison cohort, difference-in-differences estimates were +8.4 percentage points for ICS-formoterol without SABA and -8.3 percentage points for total SABA supply, but -0.2 percentage points for SABA monotherapy. The impact of the guideline change was substantial but selective. While the update facilitated transition for patients already receiving maintenance therapy, most patients on SABA-only regimens did not switch to the preferred AIR regimen. Further targeted implementation strategies beyond guideline publication are required to address this gap and ensure evidence-based care is consistently delivered. None.

PMID 42959359
阅读全文 →
PubMedChronic obstructive pulmonary diseases (Miami, Fla.)2026-10-29

Pharmacodynamic Equivalence and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate With a Next-Generation Propellant Versus Hydrofluoroalkane-134a Propellant: A Randomized Phase 3 Study in Chronic Obstructive Pulmonary Disease.

Camiolo Matthew M, Pandya Hitesh H, Jassal Mandeep M, Bednarczyk Artur A et al.

To understand the efficacy, safety, and tolerability of the budesonide/glycopyrrolate/formoterol fumarate (BGF) pressurized metered-dose inhaler (pMDI) with the next-generation propellant hydrofluoroolefin-1234ze (HFO-1234ze), a propellant with substantially lower global warming potential, versus hydrofluoroalkane-134a (HFA-134a). This randomized, 3-way crossover study (NCT06075095) assessed pharmacodynamic equivalence and safety of BGF HFO-1234ze versus BGF HFA-134a in participants with chronic obstructive pulmonary disease. Participants received twice-daily doses for 4 weeks in 3 consecutive treatment periods: A) BGF HFO-1234ze 320/18/9.6 μg, B) BGF HFA-134a 320/18/9.6 μg, and C) placebo HFA-134a in 1 of 6 randomized sequences. Two lung function endpoints (change from baseline in post-dose FEV1 area under the curve 0-4h [FEV1 AUC0-4h; primary] and morning pre-dose trough FEV1 [secondary] at Day 29) were assessed. Superiority of BGF HFA-134a versus placebo HFA-134a was assessed to demonstrate assay sensitivity. Propellant equivalence was demonstrated if 2-sided 90% CIs for ratios of BGF HFO-1234ze/BGF HFA-134a for both lung function endpoints were within 0.8-1.25 and 0.7-1.43, respectively. Safety was also assessed. 296 participants were randomized and started treatment. Superiority of BGF HFA-134a versus placebo HFA-134a, and thus, assay sensitivity for the effect of BGF was confirmed for both lung function endpoints (p<0.001). Change from baseline in post-dose FEV1 AUC0-4 and morning pre-dose trough FEV1 at Day 29 were equivalent between BGF HFO-1234ze and BGF HFA-134a (Ratio [90% CI]: 0.94 [0.88, 1.00]; 0.95 [0.84, 1.08], respectively). Adverse events were balanced across treatments. Findings support the switch from HFA-134a to HFO-1234ze in BGF pMDIs.

PMID 42954429
阅读全文 →
PubMedCureus2026-10-27

Particle Morphometrics of Glycopyrronium-Formoterol-Budesonide Inhalation Blends Influence Pulmonary Deposition and Bronchodilator Response in Chronic Obstructive Pulmonary Disease (COPD): A Gamma Scintigraphy Study.

Jain Gaurav K GK, Mishra Abha A, Chandra Nilesh N, Madan Manu M

The therapeutic efficacy of inhaled triple-combination therapy in chronic obstructive pulmonary disease (COPD) depends on efficient delivery to peripheral airways. This study evaluated the influence of particle morphometrics on pulmonary deposition and bronchodilator response to glycopyrronium-formoterol-budesonide (GFB) inhalation formulations. Three commercial GFB formulations (X, Y, and Z) delivered via metered-dose inhaler (MDI) and dry powder inhaler (DPI) were characterized using dynamic light scattering and scanning electron microscopy. In a randomized, open-label pilot study, twenty-four patients with mild-to-moderate COPD inhaled technetium-99m (99mTc) radiolabeled formulations. Regional lung deposition was assessed by planar gamma scintigraphy, and central-to-peripheral (C/P) ratios were calculated. Forced expiratory volume in one second (FEV1) was measured at baseline and 30 minutes post-inhalation. Significant inter-brand differences in particle morphometrics were observed. Brand X demonstrated a narrow particle distribution (1.3±0.26 µm) with uniform spherical morphology, while brands Y and Z showed relatively broader, polydisperse distributions with irregular particles. MDIs (MIX, MIY, MIZ) consistently outperformed DPIs (DIX, DIY, DIZ), producing greater total lung deposition (23.4% vs 13.7%; P < 0.001) and improved peripheral deposition. Among MDIs, MIX achieved higher intrathoracic deposition (28.8 ± 2.2% vs 19.0-22.5%; P < 0.001) and peripheral deposition (15.8 ± 3.0% vs 9.8-11.5%; P = 0.012), with a lower C/P ratio (0.82 vs 0.96-1.0). Greater spirometric improvement correlated with enhanced deposition, with the MIX producing the highest FEV1 increase (12.8%; P < 0.05). The findings suggest that particle size distribution, polydispersity, and surface morphology may influence pulmonary deposition and acute spirometric response in COPD. A relatively narrow respirable particle distribution may support more consistent peripheral airway deposition and short-term spirometric response.

PMID 42936311
阅读全文 →

注册免费账户还可查看另外 3075 篇文献

免费注册查看全部文献 →

了解更多formoterol